In vivo intratumor angiogenic treatment effects during taxane-based neoadjuvant chemotherapy of ovarian cancer.
BACKGROUND
The aim of our study was to analyze the effect of taxane-based chemotherapy on tumor angiogenesis in patients with advanced epithelial ovarian cancer.


METHODS
Within a prospective phase II trial, 32 patients with stage IIIC and IV ovarian cancer were treated with either two or three cycles of neoadjuvant chemotherapy prior to cytoreductive surgery. Carboplatin (AUC5) and docetaxel (75 mg/m2) were administered intravenously in a 3-weekly schedule. Changes in intratumor microvessel density (MVD) were assessed with immunohistochemistry by staining pre- and posttreatment surgical tumor specimens with panendothelial, neovascular and lymphatic vessel markers.


RESULTS
Mean values of MVD defined by CD31, CD34, CD105 and D2-40 antibodies showed 12.3, 21.0, 2.7 and 3.1 vessels per high power field (HPF) before chemotherapy and increased after treatment to 15.3, 21.8, 4.8 and 3.6 per HPF, respectively. These changes were significant for CD31 (p = 0.04) and for CD105 (p = 0.02).


CONCLUSIONS
Taxane-based chemotherapy appears to promote tumor vascularization when administered every 3 weeks. A possible explanation is the secondary recovery of MVD in response to immediate cytotoxic and antiangiogenic effects of the chemotherapy. If confirmed prospectively, these findings favor shorter treatment intervals of taxane-based chemotherapy to counteract proangiogenic recovery.
Pölcher
Martin
M
Department of Gynecology and Obstetrics, Center for Integrated Oncology, Bonn University Medical Center, Germany. martin.poelcher@ukb.uni-bonn.de
Rudlowski
Christian
C
Friedrichs
Nicolaus
N
Mielich
Marieke
M
Höller
Tobias
T
Wolfgarten
Mathias
M
Kübler
Kirsten
K
Büttner
Reinhard
R
Kuhn
Walther
W
Braun
Michael
M
D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D017024:Chemotherapy, Adjuvant; D000077143:Docetaxel; D004334:Drug Administration Schedule; D005260:Female; D005858:Germany; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D055806:Microvessels / Q000187:drug effects / Q000473:pathology; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D009389:Neovascularization, Pathologic / Q000139:chemically induced / Q000517:prevention & control*; D010051:Ovarian Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D016016:Proportional Hazards Models; D011446:Prospective Studies; D043823:Taxoids / Q000008:administration & dosage; D013997:Time Factors; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D043823:Taxoids; D000077143:Docetaxel; D016190:Carboplatin
Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:183-9
16515588
Cancer Cell. 2009 Mar 3;15(3):232-9
19249681
Am J Pathol. 1995 Jul;147(1):9-19
7541613
Int J Cancer. 2003 Mar 10;104(1):121-9
12532428
Oncogene. 2001 Jun 28;20(29):3806-13
11439344
J Clin Oncol. 2004 Feb 15;22(4):686-90
14966092
J Clin Oncol. 2007 Nov 20;25(33):5165-71
18024863
Cancer Res. 2005 Mar 15;65(6):2433-40
15781659
Blood. 1996 Jan 1;87(1):1-13
8547630
Histol Histopathol. 2009 Apr;24(4):425-35
19224445
Oncogene. 2003 Sep 29;22(42):6557-63
14528280
Expert Rev Anticancer Ther. 2004 Aug;4(4):639-47
15270667
Cancer Cell. 2008 Sep 9;14(3):263-73
18772115
Cancer Res. 1997 Jan 1;57(1):81-6
8988045
J Clin Oncol. 2008 Jan 1;26(1):76-82
18165643
Breast Cancer Res Treat. 1995;36(2):169-80
8534865
J Clin Oncol. 2003 Aug 1;21(15):2843-8
12807937
Wiad Lek. 2007;60(3-4):129-37
17726864
Cancer Lett. 1999 Apr 26;138(1-2):175-82
10378790
Int J Cancer. 1996 Jun 21;69(3):205-11
8682589
Cancer. 2001 Nov 15;92(10):2585-91
11745193
J Clin Oncol. 2001 Feb 15;19(4):1195-206
11181686
Cancer Lett. 2002 Feb 8;176(1):111-8
11790460
Lancet. 2009 Oct 17;374(9698):1331-8
19767092
Cancer Cell. 2009 Mar 3;15(3):220-31
19249680
J Clin Oncol. 2000 Jan;18(1):106-15
10623700
Nat Rev Cancer. 2006 Nov;6(11):835-45
17036040
Int J Gynecol Cancer. 2004 Sep-Oct;14(5):815-23
15361189
Ann N Y Acad Sci. 1994 Apr 18;714:165-74
8017765
Anticancer Res. 2006 Sep-Oct;26(5B):3925-32
17094423
Am J Physiol Cell Physiol. 2004 Sep;287(3):C572-9
15308462
Oncol Rep. 2009 Sep;22(3):605-13
19639211
Cancer Res. 2001 Apr 15;61(8):3369-72
11309294
Lab Invest. 2002 Sep;82(9):1255-7
12218087
N Engl J Med. 1971 Nov 18;285(21):1182-6
4938153
J Clin Oncol. 2007 Nov 20;25(33):5180-6
18024865
Crit Rev Oncol Hematol. 2009 Feb;69(2):108-24
18768327
Mol Cancer Ther. 2002 Nov;1(13):1191-200
12479700
Cell. 2000 Jan 7;100(1):57-70
10647931
Gynecol Oncol. 2009 Mar;112(3):469-74
19135712
Cancer Metastasis Rev. 2000;19(1-2):67-73
11191065
Cancer Res. 2003 Aug 1;63(15):4342-6
12907602
Clin Cancer Res. 1999 Mar;5(3):587-91
10100710
Nat Rev Cancer. 2005 Jul;5(7):516-25
15965493
Nat Rev Cancer. 2004 Jun;4(6):423-36
15170445
Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:S161-92
17161157
Cancer Res. 2007 Jan 1;67(1):281-8
17210709